➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Harvard Business School
Colorcon
Dow
Johnson and Johnson

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Avapritinib - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for avapritinib and what is the scope of patent protection?

Avapritinib is the generic ingredient in one branded drug marketed by Blueprint Medicines and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Avapritinib has forty patent family members in thirty countries.

Summary for avapritinib
International Patents:40
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 29
Clinical Trials: 8
Patent Applications: 24
What excipients (inactive ingredients) are in avapritinib?avapritinib excipients list
DailyMed Link:avapritinib at DailyMed
Recent Clinical Trials for avapritinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Blueprint Medicines CorporationPhase 1
Blueprint Medicines CorporationPhase 4
National Cancer Institute (NCI)Phase 2

See all avapritinib clinical trials

US Patents and Regulatory Information for avapritinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-002 Jan 9, 2020 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-003 Jan 9, 2020 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-001 Jan 9, 2020 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-005 Jun 16, 2021 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-002 Jan 9, 2020 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Blueprint Medicines AYVAKIT avapritinib TABLET;ORAL 212608-001 Jan 9, 2020 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for avapritinib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3057969 PA2021003 Lithuania ⤷  Free Forever Trial PRODUCT NAME: AVAPRITINIBAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/20/1473 20200924
3057969 CA 2021 00008 Denmark ⤷  Free Forever Trial PRODUCT NAME: AVAPRITINIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/20/1473 20200925
3057969 2021C/509 Belgium ⤷  Free Forever Trial PRODUCT NAME: AVAPRITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/20/1473 20200925
3057969 LUC00199 Luxembourg ⤷  Free Forever Trial PRODUCT NAME: AVAPRITINIB ET SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/20/1473 20200925
3057969 C20210005 00320 Estonia ⤷  Free Forever Trial PRODUCT NAME: AVAPRITINIIB;REG NO/DATE: EU/1/20/1473 25.09.2020
3057969 301094 Netherlands ⤷  Free Forever Trial PRODUCT NAME: AVAPRITINIB EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/20/1473 20200925
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Harvard Business School
Colorcon
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.